English
Home > Products > CAS NO 106-47-8

China CAS NO 106-47-8 Factory

We emphasize advancement and introduce new products and solutions into the market each year for CAS NO 106-47-8,106-47-8,4-Chloroaniline, We look ahead to receiving your enquires quickly and hope to have the chance to get the job done together with you inside the future. Welcome to get a seem at our organization.
CAS NO 106-47-8, We have a dedicated and aggressive sales team, and many branches, catering to our customers. We're looking for long-term business partnerships, and ensure our suppliers that they will undoubtedly benefit in both short and long run.

Related Products

Hot Products

  • Auristatin E

    Auristatin E

    Product Name:Auristatin E
    Molecular Formula:C40H69N5O7
    Molecular Weight;732.01
    CAS Registry Number;160800-57-7
  • 3-AMINO-4-CHLOROBENZONITRILE

    3-AMINO-4-CHLOROBENZONITRILE

    Product Name:3-AMINO-4-CHLOROBENZONITRILE
    Molecular Formula:C7H5ClN2
    Molecular Weight:152.58
    CAS Registry Number:53312-79-1
  • Ganciclovir

    Ganciclovir

    Product Name:Ganciclovir
    Molecular Formula:C9H13N5O4
    Molecular Weight;255.23
    CAS Registry Number;82410-32-0
  • Voglibose

    Voglibose

    Product Name:Voglibose
    Molecular Formula:C10H21NO7
    Molecular Weight;267.28
    CAS Registry Number;83480-29-9
  • Acetohydroxamic acid

    Acetohydroxamic acid

    Product Name:Acetohydroxamic acid
    Molecular Formula:C2H5NO2
    Molecular Weight:75.07
    CAS Registry Number:546-88-3
  • Acetylcysteine

    Acetylcysteine

    Product Name:Acetylcysteine
    Molecular Formula:C5H9NO3S
    Molecular Weight;163.19
    CAS Registry Number;616-91-1
  • Related Blog
  • Reviews

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • What are pharmaceutical intermediates?

    Pharmaceutical intermediates are fine chemical products in the production process from pharmaceutical chemical raw materials to bulk drugs or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. This chemical, which does not require a drug production license, can be produced in ordinary chemical plants and can be used in the synthesis of drugs as long as it reaches certain grades.

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • Why API manufacturing companies almostly in China?

    In the chemical API industry, developed countries such as the United States and Europe occupy a dominant position in the field of patented APIs with high added value by virtue of their advantages in research and development, production technology, and intellectual property protection...

  • What is Coenzyme Q10 CAS NO.303-98-0

    Coenzyme Q10 (CAS NO.303-98-0 ) is a fat-soluble antioxidant, which can activate the nutrition of human cells and cellular energy, and has the functions of improving human immunity, enhancing antioxidation, delaying ageing and enhancing human vitality.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept